tbuckley/cabot-search huggingface dataset:
SURG-03. RESECTION OF HIGHLY LANGUAGE-ELOQUENT BRAIN LESIONS PURELY BASED ON rTMS LANGUAGE MAPPING WITHOUT AWAKE SURGERY
Authors: Sebastian Ille, Nico Sollmann, Florian Ringel, Bernhard Meyer, Sandro M. Krieg
Journal: Neuro-Oncology (2016)

The resection of left-sided perisylvian brain lesions harbors the risk of postoperative language impairment. Therefore the individual patient’s language distribution is investigated by intraoperative direct cortical stimulation (DCS) during awake surgery. Yet, not all patients qualify for awake surgery. Non-invasive language mapping by repetitive navigated transcranial magnetic stimulation (rTMS) has frequently shown a high correlation in comparison with the results of DCS language mapping in terms of language-negative brain regions. To analyze the oncological and functional outcome of patients who underwent left-sided perisylvian resection of brain lesions purely based on rTMS language mapping. Four patients with left-sided perisylvian brain lesions (2 gliomas WHO III, 1 glioblastoma, 1 cavernous angioma) underwent rTMS language mapping prior to surgery. Data from rTMS language mapping and rTMS-based diffusion tensor imaging fiber tracking (DTI-FT) were transferred to the intraoperative neuronavigation system. Preoperatively, 5 days after surgery (=POD5), and 3 months after surgery (=POM3) clinical follow-up examinations were performed. No patient suffered from a new surgery-related aphasia at POM3. Three patients underwent complete resection immediately, while one patient required a second rTMS-based resection some days later to achieve complete resection. The present study shows for the first time the feasibility of successfully resecting language-eloquent brain lesions purely based on the results of negative language maps provided by rTMS language mapping and rTMS-based DTI-FT. In very select cases this technique might provide a rescue strategy with an optimal functional and oncological outcome when awake surgery is not feasible. Yet, any final statement will need more patients to be enrolled.
Study of genotypic variations and protein expression of the xCT subunit of cystine/glutamate transporter in pancreatic cancer.
Authors: T. J. Huang, D. Li, Y. Li, S. P. Kar, S. Krishnan, J. L. Abbruzzese, R. A. Wolff, M. M. Javle
Journal: Journal of Clinical Oncology (2011)

210 Background: The plasma membrane xCT cystine-specific subunit of the cystine/glutamate transporter contributes to chemotherapy resistance in pancreatic cancer by regulating intracellular glutathione levels and protecting cancer cells against oxidative stress. We previously noted that the rs7674870 single nucleotide polymorphism (SNP) of xCT correlated with overall survival in pancreatic cancer and may be predictive of platinum resistance. There are no data regarding xCT protein expression in pancreatic cancer or the functional significance of this SNP. Methods: Paraffin-embedded core and surgical biopsy tumor specimens from 49 patients with metastatic pancreatic adenocarcinoma were analyzed by immunohistochemistry (IHC) using an xCT specific antibody (Novus Biologicals). xCT protein IHC expression scores (product of intensity and percentage of staining cells) were analyzed in relation to overall survival and genotype of the patients using the one factor ANOVA test, Kaplan-Meier plot, log-rank test, and Cox regression analysis. Overall survival was measured from the date of diagnosis to the date of death or last follow-up. Results: Positive xCT expression was detected in 38 (78%) of the 49 samples, and 9 (18%) patients had high levels of expression. High xCT expression was associated with lower overall survival as compared with low expression (5.1 months versus 8.8 months; p = 0.119). In a multivariate Cox regression model with adjustment for prognostic parameters of age, sex, performance status and CA19-9 level, high xCT expression was associated with a 2.1-fold increased risk of death (p = 0.096). Performance status also correlated with overall survival (p = 0.027). Preliminary analysis on the genotype-phenotype association (n = 12) indicated that xCT expression was higher with the TT genotype than the TC/CC genotype (p = 0.115), which is consistent with the previous observation that the TT genotype was associated with reduced survival. Conclusions: These data provide supporting evidence for a possible role of cystine/glutamate transporter xCT subunit in pancreatic cancer progression and survival. Further pharmacogenomic and clinicopathologic studies are ongoing. No significant financial relationships to disclose.
Body Composition Predicts Survival in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Recipients
Authors: Asmita Mishra, Binglin Yue, Martine Extermann, Claudio Anasetti, Heather Jim, Jongphil Kim, Joseph A Pidala, Vickie E Baracos
Journal: Blood (2015)
SYK Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia
Authors: Marco Benkisser-Petersen, Maike Buchner, Arlette Dörffel, Marcus Dühren von Minden, Kerstin Leberecht, Kathrin Kläsener, Rainer Claus, Ariane Ott, Christine Dierks, Hassan Jumaa, Fabio Malavasi, Michael Reth, Hendrik Veelken, Katja Zirlik
Journal: Blood (2015)
Impact of adjuvant chemoradiotherapy on overall survival of gastric cancer patients with D2 lymphadenectomy.
Authors: A. A. Jácome, D. R. Wohnrath, C. Scapulatempo Neto, J. T. Fregnani, L. S. Viana, L. V. Santos, D. C. Maia, J. Santos
Journal: Journal of Clinical Oncology (2011)

120 Background: Adjuvant chemoradiotherapy is the standard treatment in Western countries in gastric cancer patients submitted to curative resection. However, INT 0116 pivotal trial was hampered by suboptimal surgery. There is no efficacy data of this adjuvant therapy in patients who have undergone D2 lymphadenectomy predominantly. Methods: Retrospective study with gastric adenocarcinoma patients stage II to IV M0 who underwent curative resection at Hospital de Câncer de Barretos between January 2002 and December 2007. Standard treatment at institution is D2 lymphadenectomy. Chemoradiotherapy according to INT 0116 was considered as an option for adjuvant therapy. A group of patients did not receive adjuvant therapy based on discretion of physician. We compared 3-year overall survival of the two treatments (chemoradiotherapy versus surgery alone). Survival curves were calculated according to Kaplan-Meier method and compared with log-rank test. Multivariate analysis of prognostic factors related to survival was performed by Cox proportional hazards model adjusted for age, stage and adjuvant chemoradiotherapy. Results: 185 patients were included (61% male). Median age was 61 years old. 34% were stage II, 39% stage IIIA, 16% stage IIIB e 11% stage IV M0. D2 lymphadenectomy was performed in all patients. Eighty-one patients (44%) did not receive adjuvant therapy and one hundred and four received chemoradiotherapy. 3-year overall survival by Kaplan-Meier method was 64.4% for patients who received adjuvant therapy and 61.7% for those who underwent surgery alone (p = 0.415). However, according to Cox proportional hazards model, adjuvant chemoradiotherapy was a prognostic factor for overall survival (HR: 0.52, IC 95% 0.31 – 0.87, p: 0.014), as well as stage (p &lt; 0.001). Age did not present influence on overall survival (p = 0.328). Conclusions: Adjuvant chemoradiotherapy decreased risk of death in three years in patients who underwent curative resection with D2 lymphadenectomy, with a meaningful hazard ratio in our study, and should remain as standard treatment. Ongoing trials will elucidate the role of radiotherapy in this subgroup of patients. No significant financial relationships to disclose.
Epidemiology of Fungemia in Hematological Malignancies: Preliminary Report of Seifem-2015 Survey
Authors: Marianna Criscuolo, Maurizio Sanguinetti, Giulia Dragonetti, Chiara Cattaneo, Antonio Giordano, Stelvio Ballanti, Alessandro Busca, Anna Candoni, Cecilia Caramatti, Simone Cesaro, Mario Delia, Maria Ilaria Del Principe, Maria Rosaria De Paolis, Luca Facchini, Rosa Fanci, Luana Fianchi, Federica Lessi, Francesco Marchesi, Gianpaolo Nadali, Marco Picardi, Antonio Spadea, Adriana Vacca, Adriano Venditti, Mario Tumbarello, Franco Aversa, Livio Pagano
Journal: Blood (2015)
Inherited Aortopathy Assessment in Relatives of Patients With a Bicuspid Aortic Valve
Authors: Malenka M. Bissell, Luca Biasiolli, Abhishek Oswal, Margaret Loudon, Aaron T. Hess, Hugh Watkins, Stefan Neubauer, Saul G. Myerson
Journal: Journal of the American College of Cardiology (2017)
Decitabine Facilitates the Generation of Functional Regulatory γδT Cells Via Foxp3 Gene Demethylation and NF-κB up-Regulation
Authors: Yongxian Hu, Yanjun Gu, Lixia Sheng, Kangni Wu, Jimin Shi, Yamin Tan, Xiaohong Yu, He Huang
Journal: Blood (2012)
EXTH-33. OS2966 DRAMATICALLY ENHANCES PRECLINICAL EFFICACY OF ONCOLYTIC VIRUS THERAPY
Authors: Shawn Carbonell, Ji Young Yoo, Tejaswini Nallanagulagari, Alena Cristina Jaime-Ramirez, Chelsea Bolyard, Tae Jin Lee, Jianying Zhang, Carlo Croce, Eric Wu, Manish Aghi, Balveen Kaur
Journal: Neuro-Oncology (2016)

Oncolytic viruses (OVs) are a promising immunotherapy which have largely proven to be safe in cancer patients, but with equivocal efficacy in the clinic. We recently demonstrated that therapeutic resistance to OV is driven by an integrin-dependent activation of a type-I antiviral interferon response. OS2966 is an experimental FDA Orphan Drug designated humanized monoclonal antibody which blocks CD29, the dominant β integrin subunit, and attenuates growth of bevacizumab-resistant glioblastoma xenografts. Therefore, we hypothesized that combination OS2966+OV therapy would be synergistic in the setting of glioblastoma and other solid malignancies. Indeed, OS2966 attenuated tumor cell gene expression of pro-inflammatory cytokines and STAT-1/STAT-2 activation in response to OV and, furthermore, increased OV replication and glioblastoma cell killing in vitro. Additionally, OS2966 treatment significantly increased in vivo OV replication in established subcutaneous and orthotopic xenografts. Finally, combination OS2966+OV treatment significantly enhanced anti-tumor efficacy in an orthotopic xenograft model, producing complete responses (CR) with a single cycle of treatment in 50% of animals compared to 0% CR in the OV only group. Further experiments suggested an additional ligand-independent mechanism for increased viral uptake implying OS2966 could be effective in combination with diverse types of OVs. Thus, OS2966 enhanced OV therapy by 1) increasing viral replication, 2) inhibiting anti-viral signaling, and 3) synergistically promoting tumor cell killing in vitro and in vivo. These studies suggest that OS2966 may dramatically improve the effectiveness of OV immunotherapy approaches particularly those currently under development for the treatment of glioblastoma.
IMST-19. IMMUNE PROFILING OF NF1-ASSOCIATED TUMORS REVEALS DISTINCT DIFFERENCES AMONG HISTOLOGIC SUBTYPES AND POTENTIAL FOR PATIENT-SPECIFIC SELECTION OF IMMUNOTHERAPY
Authors: Kellie B. Haworth, Michael A. Arnold, Christopher R. Pierson, Kwangmin Choi, Nicholas D. Yeager, Nancy Ratner, Jonathan L. Finlay, Timothy P. Cripe
Journal: Neuro-Oncology (2016)
Treatment strategies in patients with Metastatic Breast Cancer: real-world practice in the United Kingdom (UK) and Italy
Authors: L. Ferrari, L. Gerratana, M. Jove, M. Bonotto, M. Cinausero, D. Iacono, C. Fontanella, C. Bozza, V. Fanotto, D. Basile, G. Pelizzari, M.G. Vitale, A. Minisini, M. Mansutti, S. Russo, C. Andreetta, G. Fasola, F. Puglisi, C. Twelves
Journal: Annals of Oncology (2016)
PDTB-15. Bcl-XL AS A RADIOSENSITIZER IN THE TREATMENT OF GROUP 3 MEDULLOBLASTOMA
Authors: Maria Ruggieri, Kevin Kelley, Caitlin Powell, Mahantesh Navati, Shamik Chakraborty, Avery Wright, Marc Remke, Joel Friedman, Marc Symons
Journal: Neuro-Oncology (2016)

Medulloblastoma is the most common malignant pediatric brain tumor. Although significant progress has been made in the treatment of medulloblastoma patients over the past several decades, the five-year disease-free survival for high-risk patients, characterized by metastatic dissemination at presentation or significant post-operative residual tumor, remains relatively poor (25-40%). Group 3 medulloblastoma has by far the worst prognosis with a 5-year survival probability of approximately 30% regardless of stage. Current therapeutic modalities, in particular ionizing radiation (IR), have significant long-term side-effects within the pediatric population. Enhancement of current therapies through targeted radiosensitization may allow for improved response and lead to decreased late radiation-induced sequelae. A bioinformatics approach was employed to select a number of candidate radioresistance genes that are preferentially expressed in group 3 medulloblastoma tumors. Candidate genes were tested for radiosensitization using RNA interference. Through this approach, we have identified and validated the antiapoptotic gene Bcl-XL as an effective target for the radiosensitization of medulloblastoma group 3 tumors. The siRNA results were confirmed with ABT-263, a small molecule inhibitor of Bcl-2 family members. ABT-263 potently radiosensitized D425MED group 3 cells with a dose enhancement factor (DEF) at 40% cell death of 2.2 and a concentration of 200 nM. As ABT-263 is not blood-brain barrier permeable, a murine model utilizing a paramagnetic gadolinium-based nanoparticle delivery system is currently being developed to examine the radiosensitizing efficacy of ABT-263 in vivo. In summary, radiosensitization of group 3 tumors is expected to be useful in improving survival outcomes in patients with this type of medulloblastoma. In addition, the localized action of the radiosensitizing effect provided by the focal delivery of the drug-coated nanoparticles is expected to reduce potential ABT-263-associated side-effects.
Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024
Authors: C. Aggarwal, D. Rodriguez Abreu, E. Felip, E. Carcereny, M. Gottfried, T. Wehler, M.-J. Ahn, M. Dolled-Filhart, J. Zhang, Y. Shentu, R. Rangwala, B. Piperdi, P. Baas
Journal: Annals of Oncology (2016)
Low Efficacy of Thalidomide in Improving Response after Induction in Myeloma Patients Candidate to High-Dose Therapy.
Authors: Alessandro Corso, Silvia Mangiacavalli, Luciana Barbarano, Patrizia Zappasodi, Luciano Banfi, Luigi Montalbetti, Antonio Mazzone, Sergio Fava, Guido Frigerio, Luciano Isa, Sergio Montanara, Daniele Perego, Maria Savarè, Lilj Uziel, Alessandro Vismara, Leonardo Campiotti, Mario Fiumanò, Mario Lazzarino, Enrica Morra
Journal: Blood (2006)
CD200 Expression May Help in Differential Diagnosis between Mantle Cell Lymphoma (MCL) and B-Cell Chronic Lymphocytic Leukemia (B-CLL).
Authors: Giuseppe A. Palumbo, Giovanna Forgione, Nunzia Parrinello, Katia Cardillo, Annalisa Chiarenza, Salvatore Berretta, Fabio Stagno, Loredana Villari, Francesco Di Raimondo
Journal: Blood (2007)
Mesenchymal Stem Cells Regulate the Cell Division Symmetry of Hematopoietic Stem Cells by an Integrin Dependent Mechanism.
Authors: Sandra Gottschling, Rainer Saffrich, Anja Seckinger, Ulf Krause, Katrin Miesala, Kerstin Horsch, Patrick Wuchter, Anthony D. Ho
Journal: Blood (2005)
Unexpected Evidence That Chronic IGF-1 Deficiency In Laron Dwarf Mice Maintains High Levels of Hematopoietic Stem Cells (HSCs) In BM - Are HSCs Gradually Depleted From BM with Age In An IGF-1–dependent Manner? Implications for the Novel Effect of Caloric Restriction on the Hematopoietic Stem Cell Compartment and Longevity.
Authors: Janina Ratajczak, Wu Wan, Rui Liu, Dong-Myung Shin, Magdalena Kucia, Andrzej Bartke, Mariusz Z Ratajczak
Journal: Blood (2010)
Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)
Authors: W. Messersmith, S. Cohen, S. Shahda, H.-J. Lenz, C. Weekes, E. Dotan, C. Denlinger, B. O'Neil, A. Kapoun, C. Zhang, R. Henner, F. Cattaruzza, L. Xu, J. Dupont, R. Brachmann, S. Uttamsingh, A. Farooki, J. Berlin
Journal: Annals of Oncology (2016)
Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial
Authors: F. Ciardiello, L. Salvatore, S. Cascinu, A. Sobrero, C. Banzi, C. Barone, A. Spallanzani, T.P. Latiano, S. Siena, F. Bergamo, G. Cartenì, F. Di Costanzo, M. Di Bartolomeo, A. Santoro, A. Russo, A. Russo, M. Moscovici, E. Van Cutsem, A. Grothey, A. Zaniboni
Journal: Annals of Oncology (2016)
Differentiation of Systematically Injected Mesenchymal Stem Cells into Retina Cells in the Rat Eye.
Authors: Sung-Kyu Park, Jong-Ho Won, Sang-Byung Bae, Chan-Kyu Kim, Nam-Su Lee, Kyu-Taeg Lee, Dae-Sik Hong, Hee-Sook Park
Journal: Blood (2005)
Autologous Transplant Event-Free Survival (EFS) Following Failure of CHOP-Rituximab (CHOP-R) for Diffuse Large B-Cell Lymphoma (DLBCL) Is the Same as the EFS Following Failure of CHOP Alone.
Authors: Julie M. Vose, Philip J. Bierman, James C. Lynch, Gregory Bociek, James O. Armitage
Journal: Blood (2004)
A Prospective, Randomized, Placebo-Controlled Study of Extended-Duration Post-Discharge Thromboprophylaxis with Enoxaparin Following Arthroscopic Reconstruction of the Anterior Cruciate Ligament.
Authors: Stefan Marlovits, Gabriele Striessnig, Raimund Schuster, Roland Stocker, Monika Luxl, Siegfried Trattnig, Vilmos Vécsei
Journal: Blood (2004)
Association of Collateral Blood Vessels Detected by Arterial Spin Labeling Magnetic Resonance Imaging With Neurological Outcome After Ischemic Stroke
Authors: Adam de Havenon, David R. Haynor, David L. Tirschwell, Jennifer J. Majersik, Gordon Smith, Wendy Cohen, Jalal B. Andre
Journal: JAMA Neurology (2017)

Robust collateral blood vessels have been associated with better neurologic outcome following acute ischemic stroke (AIS). The most commonly used methods for identifying collaterals are contrast-based angiographic imaging techniques, which are not possible in all patients after AIS.To assess the association between the presence of collateral vessels identified using arterial spin labeling (ASL) magnetic resonance imaging, a technique that does not require exogenous administration of contrast, and neurologic outcome in patients after AIS.This retrospective cohort study examined 38 patients after AIS admitted to a tertiary academic medical center between 2012 and 2014 who underwent MRI with ASL.According to a prespecified hypothesis, ASL images were graded for the presence of collaterals by 2 neuroradiologists. Modified Rankin Scale (mRS) scores at discharge and other composite data were abstracted from the medical record by a neurologist blinded to radiologic data.Of the 38 patients, 19 (50.0%) were male, and the mean (SD) age was 61 (20) years. In 25 of 38 patients (65.8%), collaterals were detected using ASL, which were significantly associated with both a good outcome (mRS score of 0-2 at discharge; P = .02) and a 1-point decrease in mRS score at discharge (odds ratio, 6.4; 95% CI, 1.7-23.4; P = .005). In a multivariable ordinal logistic regression model, controlling for admission National Institutes of Health Stroke Scale score, history of atrial fibrillation, premorbid mRS score, and stroke parent artery status, there was a strong association between the presence of ASL collaterals and a 1-point decrease in the mRS score at discharge (odds ratio, 5.1; 95% CI, 1.2-22.1; P = .03).Following AIS, the presence of ASL collaterals is strongly associated with better neurological outcome at hospital discharge. This novel association between ASL collaterals and improved neurologic outcome may help guide prognosis and management, particularly in patients who are unable to undergo contrast-based radiological studies.
Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma
Authors: N Lee, S Y Moon, J-h Lee, H-K Park, S-Y Kong, S-M Bang, J H Lee, S-S Yoon, D S Lee
Journal: Blood Cancer Journal (2017)

Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma
NTOX-01. ACUTE MOTOR AXONAL NEUROPATHY AFTER VINCRISTINE INFUSION IN A 21 YEAR OLD
Authors: Mark Anderson, Duaa Jabari
Journal: Neuro-Oncology (2016)

Vincristine is a vinca alkaloid chemotherapy and cisplatin is a platinum containing chemotherapy which commonly cause a sensory or sensorimotor axonal peripheral neuropathy in adults. Prominent motor complications have primarily been reported in pediatric patients treated with vincristine. A 21 yo male presented with headache and nausea and found to have a posterior fossa mass. Resection was performed and pathology revealed a medulloblastoma. Given residual disease, craniospinal irradiation followed by cisplatin, lomustine, and vincristine was planned. Day 28 of cycle 1, patient was admitted for intractable abdominal pain, nausea, vomiting, and diarrhea following severe constipation with 30 pounds of weight loss. He elected to discontinue further chemotherapy. Day 42, he developed gradually progressive bilateral, asymmetric marked wrist and foot drop. NCS revealed low compound motor action potentials with active denervation and normal sensory nerve action potentials (SNAP). This was consistent with acute motor axonal neuropathy. CSF revealed mildly elevated protein and WBC, and 3 days of IVIG were given as a motor variant of GBS could not be completely ruled out. Campylobacter titers and GM-1 antibodies were not present. Atypical motor neuropathies from vincristine have been reported in pediatric patients, but not in adults where a sensory neuropathy is primarily a side effect of the drug. While this patient received both cisplatin and vincristine, the cisplatin likely did not contribute to the development of symptoms. As vincristine is once again part of adult glioma therapy with resurgence of PCV, the possibility of the rare toxicity of acute motor axonal neuropathy should be recognized.
Pharmacokinetic Analysis during Antifungal Prophylaxis with Posaconazole Suspension in Pediatric and Adolescent Patients after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Michaela Döring, Karin Melanie Cabanillas Stanchi, Manon Queudeville, Judith Feucht, Patrick Schlegel, Tobias Feuchtinger, Peter Lang, Rupert Handgretinger, Werner J. Heinz
Journal: Blood (2015)
Microfluidic Devices for Molecular Monitoring of Clonotypic IgH VDJ Signatures and the T(4;14) Translocation in Multiple Myeloma.
Authors: Linda M. Pilarski, Govindkrishna V. Kaigala, Jaron VanDjiken, Alexey Atrazhev, Brian J. Taylor, Andrew R. Belch, Christopher J. Backhouse
Journal: Blood (2005)